Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses new research led by the Eastern Cooperative Oncology group looking at a RCT of androgen deprivation therapy (ADT) vs ADT plus taxotere for 6 cycles. The rationale behind the trial is to look at the efficacy of chemotherapy in androgen dependent disease. Chemotherapy has proven in androgen independent disease previously. Related Reading Re: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Jocham D, Sommerauer M. Eur Urol. 2011 Apr;59(4):659. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. Bracarda S, Logothetis C, Sternberg CN, Oudard S. BJU Int. 2011 Apr;107 Suppl 2:13-20.